Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175034 | 0.87 | TRPA1 (0.45) | TRPA1TRPV4ERCC5FEN1ALDH1A1 | |
| SCHEMBL13834522 | 0.82 | TRPA1 (0.44) | TRPA1EGFRADORA2BLMNATRPV4 | |
| SCHEMBL16366823 | 0.81 | SMN1; SMN2 (0.36) | TRPA1SMN1; SMN2EGFR | |
| SCHEMBL13834392 | 0.81 | TRPA1 (0.45) | TRPA1EGFRADORA2BLMNATRPV4 | |
| SCHEMBL13834532 | 0.80 | TRPA1 (0.37) | TRPA1SMN1; SMN2EGFRLMNATRPV4 | |
| SCHEMBL13834835 | 0.77 | TRPA1 (0.38) | TRPA1ADORA2BLMNAALDH1A1 | |
| SCHEMBL13835019 | 0.76 | TRPA1 (0.37) | TRPA1ADORA2BALDH1A1 | |
| SCHEMBL13174913 | 0.75 | HPGD (0.39) | EGFRADORA2BERCC5FEN1POLB | |
| SCHEMBL799433 | 0.73 | ADORA2B (0.45) | ADORA2BLMNAERCC5FEN1ALDH1A1 | |
| SCHEMBL13834463 | 0.73 | TRPA1 (0.45) | TRPA1SMN1; SMN2ADORA2BLMNATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| US-8987278-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-24 | — | — | US | disclosed |
| EP-2634191-B1 | Process for preparing derivatives of thienopyrimidinedione | GLENMARK PHARMACEUTICALS SA (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-10-31 | — | — | US | disclosed |
| EP-2634191-A1 | Process for preparing derivatives of thienopyrimidinedione | Glenmark Pharmaceuticals S.A. (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-8507503-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507503-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-13 | — | — | US | disclosed |
| US-8507503-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-13 | — | — | US | disclosed |
| EP-2411396-B1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2411396-B1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150876-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | TRPA1 1/4885SMN1; SMN2 3000/4885EGFR 3287/4885 |
| US-20130289054-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | TRPA1 1/4885SMN1; SMN2 3000/4885EGFR 3287/4885 |
| US-20120295924-A1 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV6 | TRPA1 1/4885SMN1; SMN2 3000/4885EGFR 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.